What
are the positive changes we expect to see as a result of our activities, which will contribute to our intended impact?will be different and better in 2028?
- WMDA is an important stakeholder in the growth of novel cellular therapies, focusing on safeguarding the well-being of donors.
- WMDA is using the collective voice of its members to advocate for the interests of donors and registries in regulation and policy where donor care and the international exchange of cellular products is concerned.
WMDA will be giving its members insight, evidence and best practice to safeguard the safety and well-being of donors in all steps related to the donation.
- WMDA is globally known as the trusted repository for serious adverse events reporting.
- Lessons learnt from adverse events and reactions (SPEARs) inform donor care standards and practices and are reflected in the WMDA Standards.
A rapid alert system for disseminating information on serious adverse events and reactions to all members of the international community in contact with allogeneic donors and patients.
- Globally harmonised medical assessment criteria simultaneously protect the interest of donors whilst ensuring the safety of cellular products across international boundaries.
- International resource on all medical and ethical issues pertaining to stem cell donation, donor safety, donor outcome and the impact of donor factors on patient outcome.
- Donor protection and safety standards are aligned with developments in novel cellular therapies.
- The experiences and needs of donors are understood, communicated and reflected in donor care standards.
- WMDA is recognised as a global advocate for donor care.
- WMDA members adopt standards, protocols and procedures that safeguard the rights and safety of donors.
- National and international authorities support stem cell donation and recognise donor care standards.
borderColor | #00acc8 |
---|---|
titleColor | white |
titleBGColor | #00acc8 |
title | What will WMDA and its members do? |
Example: develop and maintain guidelines in relation to donor consent/counselling
Example: develop and maintain the SPEAR reporting tool for both related and unrelated adverse events and reactions
Example: respond to emerging infectious diseases outbreaks (e.g. Zika); expand Wiki to include the screening of cord blood donors.
Example: develop ethical principles and guidelines and tools for registries and partners involved in cellular therapy.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
|